Core Viewpoint - Quantum BioPharma Ltd. has appointed Kevin Malone as an advisor to the Board of Directors, leveraging his extensive experience in wealth management and stock trading, particularly in combating market manipulation [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [7]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in MS, and is currently in preclinical development [7]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [7]. Kevin Malone's Background - Kevin Malone has over 40 years of experience in wealth management and launched Malone Wealth in 2021, focusing on pattern recognition and data research [2]. - His investment philosophy emphasizes rigorous research, disciplined risk management, and a long-term approach to maximize returns while minimizing risk [3]. - Malone is committed to fighting market corruption and has initiated a charitable fund aimed at improving financial literacy in the U.S. public education system [4]. Strategic Importance of Malone's Appointment - The CEO of Quantum BioPharma, Zeeshan Saeed, expressed enthusiasm about Malone's expertise, particularly in naked short squeeze strategies, which will enhance the company's efforts against market manipulation [5]. - Malone's personal experiences with market corruption, including the GameStop incident in 2021, have motivated him to become a fiduciary dedicated to combating such practices [6].
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor